Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for prevention of migraine in patients with unsuccessful prior preventive treatments
2019-004497-25Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Eptinezumab with Placebo (2 arms). Primary endpoint: Change from baseline in the number of monthly migraine days. Started Mar 2020; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2019-004497-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004497-25.